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Abstract
Background: Severe sepsis and septic shock are common in intensive care and carry high mortality rates. In patients with
Gram-negative infections, early and extensive removal of endotoxin may limit the inflammatory response that characterizes
septic shock. The Alteco® LPS Adsorber (hereafter referred to cited as the lipopolysaccharide (LPS) Adsorber) can be
used for endotoxin removal and attenuate the deleterious inflammatory and clinical responses seen in septic shock.
Methods/design: The Abdominal Septic Shock – Endotoxin Adsorption Treatment (ASSET) trial is a pilot study
investigating the feasibility and safety of LPS Adsorber therapy. This pilot, multicenter, stratified, parallel, double-blinded,
randomized, phase IIa, feasibility clinical investigation will be performed in five Scandinavian intensive care
units. Thirty-two subjects with early septic shock and organ failure, following adequate resuscitation, will be
randomized to receive either: extracorporeal veno-venous hemoperfusion therapy with the LPS Adsorber or
veno-venous hemoperfusion therapy with a placebo adsorber (without active LPS-binding peptide). Patients
will be stratified by infection focus such that 20 subjects with an abdominal focus (stratum A) and 12 subjects
with a urogenital focus (stratum B) will be included in a parallel design. Thereafter, an interim analysis will be
performed and an additional 12 patients may be included in the study. The study is designed as adaptive a
priori: the patients from this study can be included in a later phase IIb study. The aim of the study is to investigate the
feasibility of LPS Adsorber therapy commenced early in the time-course of septic shock. The primary endpoint will be a
characterization of all reported unanticipated serious adverse device effects and anticipated serious adverse device
effects. Secondary outcomes are decrease in endotoxin plasma concentration, impact on clinical outcome measures
and impact on inflammatory response by LPS Adsorber therapy, as well as detailed description of the relevant
mediators bound to the LPS Adsorber. Recruitment of patients will start in September 2015.
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Discussion: The ASSET trial will give insight into the feasibility and safety of this LPS Adsorber therapy and preliminary
data on its potential clinical effects in septic shock. Moreover, this pilot trial will provide with necessary data for
designing future studies.
Trial registration: ClinicalTrials.gov Identifier NCT02335723. Registered on 28 November 2014.
Keywords: Septic shock, Endotoxins, Hemoperfusion, Gram-negative bacteria
Background
Although severe sepsis and septic shock are common in
intensive care and carry high mortality rates no specific
treatment has been established to counteract the asso-
ciated inflammatory response. Current management
may be considered supportive only and consists mainly
of effective antimicrobial therapy, removal or drainage
of infections (source control) and support of failing or-
gans [1]. Therefore, development of new treatment
methods for sepsis and septic shock is crucial for med-
ical, humanitarian and health-economic reasons.
Endotoxins are molecules found in the outer mem-
brane of the cell wall in Gram-negative bacteria. They
are potent activators of the inflammatory system
through the innate immune system and are presumably
the key triggers of the systemic inflammatory response
[2–4]. Hence, attenuating the effect of endotoxins
seems to be a logical and desirable strategy in the treat-
ment of severe sepsis and septic shock. However, so far
the use of anti-endotoxin strategies has been disap-
pointing [5–8]. On the other hand, adsorber therapy
was proven beneficial in early sepsis patients due to
intra-abdominal infections and added substantially to
improved outcome in conjunction with conventional
interventions. Improved outcome was associated with
reduced endotoxin levels in blood [9, 10]. Therefore, it
is reasonable to hypothesize that using adsorption
membranes in the treatment of selected Gram-negative
septic shock in the early phase, with a strictly defined
time-frame since the onset of clinical symptoms, may offer
therapeutic benefits. Several extracorporeal endotoxin-
removal devices, based on various endotoxin-binding
mechanisms, have been investigated with diverging results
[9, 11, 12]. Currently, at least one trial is investigating the
effect of endotoxin removal with polymyxin B cartridges
[13].
Another endotoxin removal device based on a differ-
ent concept is a novel, high-capacity adsorber system
(from Alteco® Medical AB, Lund, Sweden) with a high-
endotoxin-affinity-peptide endotoxin-binding mechan-
ism (hereafter referred to as the lipopolysaccharide
(LPS) Adsorber) that has been clinically available for
some years. This adsorber putatively binds endotoxin
and thus decreases endotoxin load in patients with
Gram-negative sepsis. Case reports and series from pa-
tients with septic shock suggest that endotoxin removal
could be achieved in clinical practice with LPS Ad-
sorber [14, 15]. However, no randomized controlled
trial has investigated the potential benefits of this LPS
Adsorber. LPS Adsorber is described as biocompatible
and no specific side effects related to it have been
reported.
We hypothesized that in patients with Gram-negative
infections, early and extensive removal of endotoxin may
limit the inflammatory response that characterizes septic
shock. This LPS Adsorber can be used for endotoxin re-
moval and, in this way, add to the currently available
strategies for sepsis treatment.
The present clinical investigation aims to collect infor-
mation on the feasibility and safety of LPS Adsorber
therapy in patients with septic shock of presumed ab-
dominal or urogenital origin. Secondary aims are to re-
port the performance of the LPS Adsorber. Specifically,
we wish to study the extent of endotoxin removal by the
LPS Adsorber, its effects on organ failure development
and the extent of organ support, as well as its possible
impact on the inflammatory response.
This trial should contribute to new knowledge since
it investigates a high-capacity peptide-binding-based
endotoxin removal that can be run for longer periods
and at higher blood flow that other endotoxin ad-
sorbers. Moreover, unlike in other device trials, the LPS
Adsorber will be compared to an identical LPS Ad-
sorber cartridge without active LPS-binding peptide.
Thus, a double-blinded randomized controlled trial will
be possible to perform.
Finally, the ultimate objective of this pilot investigation
is to provide the necessary information on the magni-
tude of the clinical effects of the LPS Adsorber, thus
providing the basis for further investigations in a larger
population.
Methods/design
This is a pilot, multicenter, stratified, parallel, double-
blinded, randomized, phase IIa, feasibility clinical
investigation and is reported according to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines [16]. Subjects will be
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enrolled in accordance with an adaptive design, with
an interim analysis allowing enrollment of additional
patients until an adequate sample size is attained, to
show the safety and the feasibility or lack thereof of
LPS Adsorber therapy in the target patient population.
The study will be conducted in five general intensive
care units (ICU) in Uppsala, Sweden, Bergen and Oslo,
Norway, and Tampere and Kuopio, Finland. These ICUs
will be screened around the clock to identify potential
patients. Initially, 32 subjects admitted to the ICU with
confirmed septic shock will be stratified in accordance
with the origin of their suspected endotoxemia, i.e., 20
septic shock subjects with an abdominal focus (stratum
A) and 12 subjects with a urogenital focus (stratum B)
will be randomly allocated to the active LPS Adsorber
group (Interventional Medical Device group, IMD
group): current best practice in combination with LPS
Adsorber therapy or placebo device group (control
group): current best practice in combination with pla-
cebo adsorber therapy (identical LPS Adsorber cartridge
without active LPS-binding peptide). The random alloca-
tion to either therapy arm in each stratum will be per-
formed in a 1:1 ratio.
An interim analysis will be performed after all subjects
in their corresponding stratum have completed their
participation in the investigation to reveal whether 12
additional subjects are required. The enrollment plan in
the clinical investigation is summarized in Fig. 1.
Fig. 1 Enrollment plan for each stratum and interim analysis. *Optional enrollment of sepsis subjects (of abdominal, urogenital or both origins)
after interim analysis
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The study has an adaptive design and thus the investi-
gators have made an a-priori decision to include the pa-
tients from this study in a later phase IIb study aiming
to investigate and report possible outcome benefits of
the therapeutic intervention.
Inclusion criteria
Upon enrollment (i.e., pretreatment phase), subjects ad-
mitted to the ICU with suspected endotoxemia will be
screened for fulfillment of the “Illness severity criteria”
confirming early stage severe sepsis.
Within 6 h of enrollment, subjects who also fulfill the
“Treatment criteria” confirming septic shock will be eli-
gible for randomization.
The subjects have to meet all of the following
criteria to be eligible to enter the clinical
investigation:
Illness severity criteria
At enrollment, subjects must meet the inclusion criteria
#1 through #5 listed below to be eligible to enter the
clinical investigation:
1. Subjects must have suspected infection of abdominal
or urogenital origin for which the subject is
receiving intravenous antimicrobial therapy
2. Subjects must have systemic inflammatory response
syndrome (SIRS), i.e., they must meet at least two of
the criteria defined below during the 36 h prior to
clinical investigation entry:
(a) Abnormal body temperature:
i.) Fever: core temperature (measured via rectum,
urinary bladder, central catheter) above 38 ° C
(100.4 ° F), or
ii.) Hypothermia: core temperature
(measured via rectum, urinary bladder,
central catheter) below 36 ° C (96.8 ° F)
(b) Heart rate above 90 beats/min
(c) Spontaneous respiratory rate above 20 breaths/
min or PaCO2 < 32 mmHg (4.3 kPa) or
concurrent use of mechanical ventilation for an
acute process
(d) White blood cell count (WBC) of >12,000 cells/
mm3 or <4000 cells/mm3 or a >10% increase in
immature neutrophils
3. Subjects must have clinical signs consistent with
organ dysfunction, i.e., they must meet at least one
of the following criteria during the 6 h prior to
clinical investigation entry:
4. Subjects, independent of gender, must be aged 18
years or older
5. Subjects or legally acceptable representatives, as
appropriate, are willing and able to provide signed
informed consent
Treatment criteria
6. Prior to randomization, subjects must meet all
inclusion criteria (#7 through #11) listed below
to be assigned to a treatment group:
7. Subjects must have septic shock according to the
modified septic shock criteria, i.e., Illness severity
criteria #1 through #3 are still fulfilled
8. Subjects must score a Sequential Organ Failure
Assessment (SOFA) score of 10 or higher, and a
Simplified Acute Physiology Score (SAPS II) of 58
or higher
9. Appropriate vascular access must have been
obtained
10. Subjects must have received ≥30 mL/kg of
intravenous fluid within the 6 h prior to
randomization
11. Subjects must have a continuous requirement for
vasopressor support (at least one of the vasopressors
must be given as listed below) for at least 2 h prior
to randomization to maintain mean arterial pressure
(MAP) >65 mmHg or systolic arterial pressure >90
mmHg with reasonable attempts made to wean the
subject from vasopressor support. Careful evaluation
is made so that vasopressor dependency is not only
related to sedation. Required vasopressor support
includes at least one of the following vasopressors
administered as described below (and allows for
combination therapy where other vasopressors are
given with modified administration regimen):
(a) Norepinephrine ≥0.07 μg/kg/min
(b) Dopamine ≥10 μg/kg/min
(c) Phenylephrine ≥35 μg/kg/min
(d) Epinephrine ≥0.07 μg/kg/min
(e) Vasopressin ≥0.03 units/min
12. Subjects must be able to initiate the clinical
investigation intervention within 12 h of fulfillment
of the Illness severity criteria
Exclusion criteria
Subjects who meet any of the exclusion criteria listed below
will not be permitted to enter the clinical investigation:
 Sepsis-induced organ dysfunction for longer than 12
h prior to the time point for achieving “Illness
severity criteria fulfilled”
 Vasopressor therapy (at any dose) for longer than 8
h (not including the time spent in the operation
theatre) prior to the start of the therapy with the
investigational device
 Preexisting irreversible medical conditions such as:
○ Poorly controlled neoplasms or hematologic
disease (i.e., indication of disseminated cancer
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outside the suspected primary tumor and
hematologic disease not in remission)
○ End-stage cardiac disease
○ Cardiac arrest requiring cardiopulmonary
resuscitation or with pulseless electrical activity
or asystole within the past 7 days
○ End-stage lung disease; end-stage liver disease
○ HIV/AIDS with known end-stage processes
○ Other uncorrectable medical condition(s) deemed
by the clinical investigator to hinder the subject to
adhere to the fulfillment of the activities described
in the Clinical Investigation Plan (CIP)
 Extreme illness, i.e., subject is moribund and death
is perceived to be imminent (within 24 h)
 Recent or current participation (≤30 days) in
another interventional sepsis trial
 Recent or current treatment (≤30 days) with an
adsorption product, including the LPS Adsorber
 Treatment with an investigational medicinal product
for any indication within the last 30 days before
enrollment in the clinical investigation
 Pregnancy
 Contraindications to the use heparin or protamine,
as in case of, but not limited to:
○ Prior heparin-induced thrombocytopenia II
(HIT II)
○ Prior intracranial bleeding of any cause up
to 90 days before inclusion in this clinical
investigation
○ Prior neurosurgery up to 90 days before
inclusion in this clinical investigation. Prior
hemorrhagic stroke up to 90 days before
inclusion in this clinical investigation
○ Fish allergy
 Other abdominal inflammatory conditions such as,
but not limited to:
○ Suspected pancreatitis (serum amylase
(s-amylase) level at least three times the upper
limit of normal (ULN))
○ Suspected fulminant hepatitis
○ Suspected gastric/duodenal ulcer-related
gastrointestinal perforation
 Perforation of hollow organ linked to trauma within
48 h before enrollment in the clinical investigation
 Laparotomy reveals isolated gastric ulcer
 Subjects and/or their immediate family are directly
affiliated to investigative site personnel in this
clinical investigation (immediate family is defined as
a spouse, parent, child or sibling, whether biological
or legally adopted)
Intervention
Upon enrollment (i.e., pre-treatment phase), subjects ad-
mitted to the ICU with suspected endotoxemia will be
screened for fulfillment of the “Illness severity criteria”
confirming the early stages of severe sepsis. Within 6 h
of enrollment, subjects who also fulfill the “Treatment
criteria” confirming septic shock will be eligible for
randomization. Randomization to either of the treatment
groups will be performed as close as possible to the start
of treatment with the LPS Adsorber or placebo device.
Treatment with the LPS Adsorber or placebo device
must be initiated within 6 h (day 1) following fulfillment
of the “Treatment criteria” and given for 6 h. A second
device treatment will be performed 24 h after the end of
the first device treatment on day 2, as long as there is no
evidence that treatment with the investigational device
will not be beneficial or will indicate an unnecessary risk
for subjects (for example, if the subject is free of vaso-
pressor support).
The treatment with the LPS Adsorber or placebo can
be discontinued at any time on the decision of the at-
tending physician. At least one 2-h treatment session is
required to fulfill the treatment protocol.
After treatment with the LPS Adsorber or placebo is
finalized (post-treatment phase), subjects will be moni-
tored until they are ready for ICU discharge or deceased.
Discharge from hospital and mortality at 28 days since
enrollment will also be collected. Figure 2 and Table 1
summarize the participant timeline of the clinical
investigation.
Concomitant therapy
Medication, which is considered necessary for the sub-
jects’ safety and wellbeing, may be given at the discretion
of the investigator. Relevant medications or other inter-
ventions include, but are not limited to current best
practice for the treatment of septic shock as described in
the Surviving Sepsis Campaign guidelines [1].
Administration of concomitant medication/therapy
during the conduct of the investigation may lead to
withdrawal of the subject from the clinical investigation.
Prohibited medications/therapies include:
 Medications without a marketing approval in the
country of the site
 Colloids (with the exception of albumin) for use in
fluid resuscitation
 The use of renal replacement therapy (RRT)
concomitantly with the use of the LPS Adsorber or
placebo device is allowed between device therapies
on day 1 and day 2, and after the end of therapy
phase on day 2
Blinding
This is a double-blinded study. Data is collected by an
independent contract research organization (TFS Trial
Form Support AB, Lund, Sweden). Neither health care
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providers nor Steering Committee members, investiga-
tors or statisticians will have access to group allocation
of subjects. The LPS Adsorber contains a designed syn-
thetic peptide developed for endotoxin adsorption. The
placebo comparator device differs from the LPS Ad-
sorber only in that no peptide component (i.e, active
component) has been attached to the matrix. Both the
LPS Adsorber and the placebo device will be relabelled
for the purpose of this clinical investigation. The investi-
gational site(s) will be provided with emergency code
break envelopes for all subjects.
Randomization
Screening will be web-based. Patients are randomized to
either the LPS Adsorber or placebo adsorber arms by
being treated with a blinded cartridge on site starting
with the lowest serial number. The abdominal focus
(stratum A) and the urogenital focus (stratum B) pa-
tients are kept apart by different serial numbers. This re-
sults in double-blinding, stratification by sepsis focus
and randomization in blocks.
Primary objective
The primary objective of this clinical investigation is to
investigate the feasibility, safety and possible benefits of
the LPS Adsorber in treating patients with septic shock
with presumed endotoxemia of abdominal or urogenital
origin.
Secondary objective
The secondary objectives are:
 To investigate the ability of the LPS Adsorber to
reduce levels of endotoxin in plasma during and
directly after treatment with the investigational
device
 To investigate the impact of the LPS Adsorber on
clinical outcome
 To investigate the impact of the LPS Adsorber on
the inflammatory response in septic shock
 To investigate the content bound to the LPS
Adsorber in a subset of subjects after treatment end
Endpoints
Primary endpoint
Primary endpoint is characterization of all reported un-
anticipated serious adverse device effects and anticipated
serious adverse device effects.
Secondary endpoints
 Relative change from baseline in plasma endotoxin
(p-endotoxin) levels during (i.e., at 2 h) and
Fig. 2 Overall clinical investigational design. *Treatment with IMD or placebo device will be repeated on Day 2, i.e. 24 h after end of treatment
on day 1. § Randomization will be performed as close as possible to start of treatment start (time-point O h) on Day 1
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immediately after end (i.e., at 6 h) of therapy with
device, on both day 1 and day 2
 Monitoring of clinical outcome parameters during
stay at ICU:
○ Relative change from baseline in SOFA score
(total and organ specific) measured once daily
and up to 120 h (or time for ICU discharge,
whichever comes first) after start of therapy
with device
○ Relative change from baseline in the
monitoring of renal function
○ Relative change from baseline in the
monitoring of liver function
○ Relative change from baseline in
circulatory support
○ Relative change from baseline in
respiratory support
○ ICU mortality
○ ICU length-of-stay (LOS) up to 28 days
 Monitoring of clinical outcome parameters during
stay at hospital following ICU discharge:
○ The total extension of renal support
○ 28-day mortality
○ Hospital-LOS up to 28 days
 Monitoring of inflammatory response biomarkers:
○ Inflammatory triggers and markers
○ Acute phase protein markers
○ Plasma cytokines
 Determination of the molecular components
extracted from blood circulation and captured in the
LPS Adsorber
 Characterization of all reported adverse events
(regardless of attribution), adverse device effects and
device deficiencies
Participant withdrawal
Participation in the clinical investigation is voluntary
and subjects (or their legally accepted representa-
tives) may discontinue their participation at any
time.
Subjects may be withdrawn from investigational treat-
ment and assessments at any time if deemed necessary
by the investigator.
Potential reasons for withdrawal of subjects from this
clinical investigation are:
 Screening failure (if any inclusion criterion is not
fulfilled or if any exclusion criterion is fulfilled)
 The decision of a subject or legally acceptable
representative(s), as appropriate, to withdraw from
the clinical investigation (including if the subject
withdraws informed consent)
 Administration of concomitant medication or
procedure prohibited by this investigation plan
 Need of other intervention, for medical reasons, that
leads to the interruption of the sepsis treatment.
Examples:
○ Imminent need of surgery
○ Imminent need of continuous renal
replacement therapy (CRRT), defined as
 Plasma potassium >6.5 mmol/L despite
other therapeutic options
 Life-threatening fluid overload
○ Computed tomography (CT) scan
 Pregnancy
 Subject is lost to follow-up
Severe adverse reactions
The LPS Adsorber is a class IIa medical device and does
not include any drugs or toxic substances that enter the
blood circulation. All components in the LPS Adsorber
are biocompatible. The capturing-peptide component is
nontoxic, and cannot be released during rinsing or ther-
apy procedures as it is covalently bound to the matrix.
The LPS Adsorber is part of an extracorporeal hemoper-
fusion system which is supplied sterile and only for sin-
gle use.
All serious adverse events and serious adverse device
effects are promptly reported by the investigation site to
Clinical Drug Safety Support at the contract research
organization (TFS Trial Form Support AB, Lund,
Sweden) within 24 h of learning about the event, regard-
less of the time that may have elapsed from the time the
event occurred and these will be evaluated and recorded.
Amendments
Protocol amendments will be made by the Steering
Committee and submitted to the ethical boards in each
participating country for approval. The protocol pre-
sented is version 5 from 2 March 2016.
Acquisition of data
An eCRF (electronic Case Report Form) system will be
used. Data validation and data queries will be handled by
the contract research organization‘s Data Management
Team (TFS Trial Form Support AB, Lund, Sweden).
Data handling and record keeping
A monitor from the contract research organization (TFS
Trial Form Support AB, Lund, Sweden) will perform
monitoring activities at the assigned clinical investiga-
tional site(s) in accordance with the monitoring plan.
Management and storage of data will be handled by the
contract research organization.
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Data ownership and publication policy
The investigators and the sponsor will be joint owners of
all materials and all results. Any publication shall be
subject to the prior review and approval of the sponsor,
such approval is not to be unreasonably withheld. The
sponsor shall not have a right for veto in any correct fac-
tual part of any planned publication.
Statistics
Power calculation
Since this is a pilot study, no sample size calculation was
possible or has been performed. The sample size was
chosen for practical reasons, and aimed to allow recruit-
ment of all subjects in the first enrollment period (i.e.,
stratum A and stratum B) within a year, and within six add-
itional months for subjects in the second enrollment
period. Data from this pilot investigation will provide infor-
mation for designing future studies with the LPS Adsorber.
Endpoints
No primary performance variables will be collected in
the present clinical investigation. The statistical analyses
of secondary endpoints will be descriptive.
Analysis sets
The following analysis sets will be used for the statistical
analysis:
The Full Analysis Set (FAS) will consist of all random-
ized subjects who were treated with the investigational
device or placebo device for at least 2 h on day 1.
The Per Protocol Set (PPS) will consist of subjects
from the FAS who completed at least 2 h of therapy with
the investigational device or the placebo device on day 1
and on day 2. Additionally, the subjects in the PPS will
not have any major CIP violations that will affect the
evaluation. Major CIP violations will include but are not
limited to the following:
 Nonfulfillment of all inclusion criteria
 Fulfilling at least one exclusion criteria
The FAS is considered as the primary analysis dataset,
and will be used for all performance analyses. The analy-
sis(es) that will be repeated using the PPS will be further
described in the SAP. Major discrepancies between the
results from the FAS and the PPS analyses will be com-
pared and discussed.
The Safety Set will consist of all randomized subjects
who started therapy. Safety summaries will be performed
on the Safety Set.
Interim analysis
An interim analysis will be performed after all subjects
in their corresponding stratum have completed their
participation in the investigation to assess whether 12
additional subjects are required.
Discussion
To date, there is no specific therapy for the inflammatory
response induced by bacteria in sepsis. Given its role in
triggering inflammatory responses, endotoxin could play a
central role in inducing organ failure in Gram-negative
sepsis. Endotoxin removal with an endotoxin-specific,
high-affinity, high-capacity adsorber system is, therefore,
an attractive therapeutic option. The LPS Adsorber used
in this study fulfills these characteristics.
The key goal of this study is to identify patients who
might benefit from endotoxin removal. This goal is
achieved by including severely ill septic shock patients
with presumed endotoxemia and initiating endotoxin re-
moval therapy early. The objective of the ASSET study is
to investigate the safety and feasibility of LPS Adsorber
therapy and to provide data for further studies.
Trial status
Recruitment of patients started in September 2015.
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